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tumors [1, 2]. It can arise from the epithelial surfaces of the 
head and neck area, the genitourinary tract and the anorec-
tum [3, 4]. Fifty-five percent of all mucosal melanomas are 
localized in the head and neck area, of which one-third are 
oral mucosal melanomas and two-thirds sinonasal malig-
nant melanomas (SNMM) [1, 2, 5, 6]. The latter represents 
a highly aggressive subgroup of this disease [1, 2] and, 
consequently, a diagnostic and therapeutic challenge for all 
involved specialists.
Regarding clinical observations, two distribution pat-
terns of mucosal malignant melanoma exist: (a) uni- and 
(b) multilocular malignant melanoma [7, 8]. The latter were 
arbitrarily defined in the past in the context of genitourinary 
tract melanomas as tumors with growth in multiple loca-
tions at initial diagnosis or local recurrence outside the scar 
tissue [8]. However, the prevalence of multilocular sinonasal 
malignant (mSNMM) melanomas as well as its therapeutic 
and prognostic implications were not studied in detail.
Surgery (either open or endoscopic) has been shown to 
be the first-line treatment [2, 6, 9], whereas postoperative 
radiotherapy or radiotherapy alone have been discussed 
controversially. Some studies have shown increased local 
tumor control without increase in overall survival [3, 10–
13], whereas others did not find any better local control 
with postoperative radiotherapy [1, 2, 14].
The aim of this study was to determine the prevalence 
of mSNMM, to analyze its outcome in relation to patients 
with unilocular sinonasal malignant melanoma (uSNMM) 
and to assess potential implications regarding its treatment.
Materials and methods
The ethical committee of the local authority permits retro-
spective studies on patient data as long as they are imposed 
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by a member of the treatment institution and as long as 
anonymized data are used. All patients with SNMM treated 
at our institution between 1992 and 2011 were included in 
this study. Patients with mucosal malignant melanoma of the 
head and neck area other than SNMM were excluded, also 
those with SNMM and incomplete data or primarily pal-
liative treatment. The medical records were reviewed for age, 
gender, pigmentation of SNMM (melanotic vs. amelanotic), 
origin and distribution pattern of SNMM (uni- vs. multiloc-
ular), treatment modalities such as outcome parameters. A 
multilocular distribution pattern was defined as the presence 
of multiple lesions with different localizations at the initial 
diagnosis, whereas the criterion of a margin free of cells of 
malignant melanoma between the lesions had to be fulfilled. 
Loco-regional tumor control and survival were analyzed with 
respect to the following factors: age, gender, pigmentation of 
SNMM, origin, distribution pattern and modality of therapy 
(i.e., the surgical approach and the use of a postoperative 
radiotherapy). Due to the complex anatomical region of the 
sinonasal system, it was not possible to obtain surgical mar-
gins as recommended in the treatment of cutaneous malignant 
melanoma. Therefore, surgical margins were defined arbi-
trarily: after resection of the tumor, resection margins were 
assessed separately. If they were found to be free of tumor 
upon histological examination, we considered the removal to 
be R0. In cases, in which the SNMM could macroscopically 
be removed completely with the inability to obtain an addi-
tional marginal specimen (i.e., due to the proximity of vital 
structures), margins were classified to be “close”.
Differences in the two different groups of patients 
(uni- vs. multilocular) at time of the initial treatment were 
assessed using Fisher’s exact, the Chi-square (nominal 
variables) and Mann–Whitney U tests (age). Kaplan–Meier 
curves were assessed using the Cox regression analysis 
(age) and the log-rank test (all other factors) to analyze the 
outcome of the two patient groups.
Results
Baseline characteristics
Twenty-five patients were identified and included in the 
analysis. The tumors of 7 patients (28 %) were defined as 
mSNMM, the remaining 18 patients (72 %) as uSNMMs. 
Their characteristics are shown in Tables 1 and 2. Statistical 
analysis did not reveal any significant differences between 
uSNMM and mSNMM except for the frequency of suffi-
cient, close or insufficient surgical margins (P < 0.001) and 
the use of a postoperative radiotherapy (P = 0.007). All 
patients with close or insufficient surgical excision, except 
for one 82-year-old woman, underwent postoperative 
radiotherapy. This female patient refused a postoperative 
radiation. A further patient with uSNMM and sufficient 
surgical margins underwent postoperative radiation due to 
extension of the primary into the maxillary sinus.
Loco-regional tumor control
Loco-regional tumor control failed in 15 patients (60 %), 
of whom 3 patients (12 %) showed persistence after the 
first-line therapy and 12 patients presented with local recur-
rence (48 %). Of the patients with failure of local tumor 
control, additional three patients (12 %) developed delayed 
lymph node metastasis of the neck during follow-up. Loco-
regional tumor control of patients with mSNMM was non-
significantly lower compared to patients with uSNMM 
(P = 0.094). Age, gender, tumor origin and pigmenta-
tion, surgical approach and postoperative radiotherapy did 
not have any significant influence on loco-regional tumor 
control.
Distant metastasis
14 (56 %) out of the 25 patients developed distant metasta-
ses during the follow-up period. Distribution pattern such 
as all the other analyzed factors had no influence on the 
development of distant metastases.
Disease-free survival
Overall disease-free survival (DFS) was 58.7 % after 1 year, 
32.6 % after 2 years and 18.6 % after 5 years (Fig. 1). 
A trend was observed comparing the DFS of patients with 
amelanotic and melanotic melanoma with the latter show-
ing better results (P = 0.068). Patients with mSNMM 
showed a significantly inferior DFS compared to patients 
with uSNMM (P = 0.023), representing a DFS of 28.6 % 
after 1 year such as 14.6 % after 2 and 5 years in patients 
with mSNMM compared to 70.6, 41.2 and 23.5 %, respec-
tively, in patients with mSNMM (Fig. 2). All the other 
analyzed factors did not show any significant influence on 
DFS.
Disease-free and overall survival
Only three deaths were reported to be disease-related, 
resulting in a disease-specific survival (DSS) of 95.7 % 
after 1 and 2-years and 87.7 % after 5 years. With only 
three disease-related deaths, the number of incidents was 
too small to perform a statistical analysis.
Overall survival (OS) was 95.4 % after 1 year, 72.1 % 
after 2 years and 55.4 % after 5 years. Mean survival was 
67 months (95 % CI 46–88 months). Multilocularity such 
as all the other analyzed factors did not show a statistically 
significant effect on DSS and OS (Fig. 1).
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Discussion
We report two major findings: (1) Multilocularity was 
shown in almost 30 % of our SNMM patients. (2) DFS of 
patients with mSNMM is significantly worse compared to 
patients with uSNMM. However, overall survival of these 
two distinct subgroups of patients does not differ.
Multilocular sinonasal malignant melanoma
SNMM is an aggressive disease showing failure of loco-
regional tumor control in almost two-thirds and distant 
metastasis in more than half of patients during the follow-
up period. Regarding loco-regional tumor control, our 
results lie within those published by other authors [11, 
13, 15], whereas survival seems to be slightly better than 
reported by others [1–3, 9, 11, 15–18]. On the basis of 
clinical observations, this study proposes the existence of 
a multilocular type of SNMM (mSNMM), which has not 
been examined adequately up to present. In contrast to 
reports studying mucosal melanomas other than its sinona-
sal counterparts, we did not define recurrences outside the 
scar tissue as “multilocular”. Potentially, an inadequately 
treated uSNMM showing local recurrence would have been 
mistaken as mSNMM by using this definition. The preva-
lence of mSNMM in our patient cohort is 28 %, showing 
an inferior loco-regional tumor control and an inferior DFS 
compared to uSNMM. However, overall survival of SNMM 
did not differ among uni- or multilocularity. Similar find-
ings were attributed to vulvovaginal mucosal melanomas 
Table 1  Characteristics of patients with SNMM
SNMM sinonasal malignant melanoma, n/a not available
a  KIT mutation status available in 12 patients (45 %)
b  BRAF and NRAS mutation status available in four patients (16 %)
c  Temozolomide, dacarbazine, cisplatin, eldisine, taurolidine, gemcitabine, oxaliplatin, capecitabine, paclitaxel
d  Ipilimumab, sorafenib, bevacizumab
e  Interferon alpha
All patients  
(n = 25 patients)
Uni-SNMM  
(n = 18 patients)
Multi-SNMM  
(n = 7 patients)
Statistical  
significance
Age 65.9 ± 12.4 years 65.9 ± 11.6 years 65.9 ± 15.2 years P = 0.79
Female/male 17/8 patients (68/32 %) 13/5 patients (72/28 %) 4/3 patients (57/43 %) P = 0.64
Histology
 Amelanotic 8 patients (32 %) 5 patients (28 %) 3 patients (43 %) P = 0.66
 Melanotic 16 patients (64 %) 12 patients (67 %) 4 patients (57 %)
 N/a 1 patient (4 %) 1 patient (6 %)
Tumor origin P = 0.20
 Nasal cavity 15 patients (60 %) 9 patients (50 %) 6 patients (86 %)
 Paranasal sinuses 5 patients (20 %) 4 patients (22 %) 1 patient (14 %)
 Nasal septum 5 patients (20 %) 5 patients (28 %)
KIT mutationa 0 patients (0 %)
BRAF mutationb 0 patients (0 %)
NRAS mutationb 1 patient (4 %) 1 patient (14 %)
N + neck at diagnosis 0 patients (0 %)
Surgical approach P = 1.00
 Transnasal 17 patients (72 %) 12 patients (67 %) 5 patients (71 %)
 Open 8 patients (28 %) 6 patients (33 %) 2 patients (29 %)
Surgical margins P < 0.001
 Sufficient 15 patients (60 %) 15 patients (83 %)
 Close 2 patients (8 %) 1 patient (6 %) 1 patients (14 %)
 Insufficient 8 patients (32 %) 2 patients (11 %) 6 patients (86 %)
Postoperative radiotherapy 10 patients (40 %) 4 patients (22 %) 6 patients (86 %) P = 0.007
Systemic therapy
 Chemotherapy 6 patients (24 %) 4 patients (22 %) 2 patients (29 %) P = 1.00
 Targeted therapyd 5 patients (20 %) 3 patients (17 %) 2 patients (29 %) P = 0.60
 Othere 1 patient (4 %) 1 patient (14 %)
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and also to SNMM in prior studies [7, 8]. In our opinion, 
the inferior loco-regional control rate and DFS are primar-
ily due to the difficulty in obtaining sufficient resection 
and not due to a higher aggressivity of these tumors. On 
the other hand, the question why some small tumors show 
a multilocular distribution pattern and other, considerably 
larger, tumors remain unilocular is unanswered.
Postoperative radiotherapy
In the context of the aggressive behavior of SNMM, authors 
argue that the high incidence of loco-regional failures justifies 
the use of a postoperative radiotherapy and recommend this 
therapy, especially in extensive disease [10, 11]. However, the 
efficacy of radiotherapy in SNMM is discussed controver-
sially. While some authors consider SNMM to be relatively 
radioresistant [15, 19] and did not find advantages in tumor 
control with postoperative radiotherapy [1, 2, 14], others 
detected better local tumor control rates without improving 
survival [3, 10–13]. An improved loco-regional tumor control 
would be suitable, especially in cases of mSNMM, in which 
it is difficult to obtain sufficient surgical margins. Statisti-
cal analysis, however, did not reveal any difference among 
patients treated with or without postoperative radiotherapy. 
Nevertheless, baseline characteristics of patients with and 
without radiotherapy were considerably different. While 
patients with radiotherapy were predominantly suffering from 
mSNMM and showed insufficient or close margins, those 
without had safe margins and uSNMM biasing the whole 
analysis. To overcome this hurdle, a large prospective rand-
omized trial would be needed. Recently, neutron therapy has 
demonstrated improved outcomes in a number of radioresist-
ant histologies [19]; among others, this therapy was effective 
in the treatment of head and neck malignant melanomas [19]. 
At present, the lack of an adjuvant therapy with proven effi-
cacy demands consequent follow-up examinations including 
PET/CT imaging, which has been showed to be the imaging 
of choice during follow-up [20].
Table 2  Patients with sinonasal malignant melanoma
f female, m male, histo histology, mel melanotic, amel amelanotic, n/a not applicable, distrib distribution, uni unilocular, multi multilocular, 
marg surgical margins, suff sufficient, insuff insufficient, postop RT postoperative radiotherapy, mts months, LR local failure of therapy, RR 
regional failure of therapy, DM distant metastasis, FU follow-up, DUTM death unrelated to melanoma, DOD death of disease, AWD alive with 
disease, AWOD alive without disease, LTFU lost to follow-up
No Age/sex Histo Origin Distrib Approach Marg Postop RT LR (mts) RR (mts) DM (mts) FU (mts) Outcome
1 f/76 mel Nasal cavity uni Transnasal suff No 44 No No 83 DUTM
2 f/78 amel Paranasal sinuses uni Transnasal suff No 18 No No 23 DUTM
3 m/75 amel Nasal cavity uni Transnasal suff No 7 No No 24 DUTM
4 f/68 mel Nasal cavity uni Transnasal suff No No No 22 31 DUTM
5 m/63 amel Nasal cavity uni Transnasal suff No No No 55 65 DUTM
6 m/40 mel Nasal cavity multi Transnasal insuff Yes tp 24 38 47 DUTM
7 f/78 mel Paranasal sinuses uni Open close Yes 81 No No 88 DUTM
8 f/72 mel Nasal cavity uni Transnasal suff No No No No 124 DOD
9 f/71 mel Nasal cavity uni Open suff No 41 No 61 72 AWD
10 m/50 mel Nasal septum uni Transnasal suff No 63 No 95 132 DUTM
11 f/73 mel Nasal cavity uni Transnasal suff No 8 No 8 12 DOD
12 f/66 amel Nasal septum uni Transnasal suff No 23 No No 70 AWOD
13 m/53 amel Nasal cavity multi Transnasal insuff Yes tp 5 11 17 DUTM
14 f/52 mel Nasal septum uni Transnasal suff No 18 No No 63 AWOD
15 m/68 mel Paranasal sinuses uni Open suff Yes No No 4 13 DUTM
16 m/79 amel Paranasal sinuses multi Open insuff Yes No No 17 17 LTFU
17 f/82 amel Nasal cavity multi Transnasal insuff No tp No 10 10 LTFU
18 f/49 mel Paranasal sinuses uni Open insuff Yes No No 8 14 DUTM
19 f/57 mel Nasal cavity uni Open insuff Yes No No No 59 AWOD
20 f/64 mel Nasal cavity multi Transnasal close Yes 8 No No 58 AWOD
21 f/77 mel Nasal cavity multi Transnasal insuff Yes No No 10 15 AWOD
22 f/66 mel Nasal cavity multi Open insuff Yes No No No 21 AWOD
23 f/63 amel Nasal cavity uni Transnasal suff No 7 No 38 41 DOD
24 f/43 mel Nasal septum uni Transnasal suff No No No No 1 AWOD
25 m/84 n/a Nasal septum uni Open suff No 13 20 23 24 AWD
127Eur Arch Otorhinolaryngol (2015) 272:123–129 
1 3
Systemic therapy
Mutations of the KIT gene are reported to be present in up 
to 20 % of the cases with mucosal malignant melanoma; 
aberrations of the BRAF gene usually are absent in these 
patients [21–23]. Therefore, BRAF inhibitors, for which 
encouraging tumor regressions of cutaneous malignant 
melanoma have been observed [24], do not represent a 
treatment option for patients with SNMM. In contrast to 
the prevalence of mucosal melanomas with KIT mutations 
reported in the literature, none of our patients undergoing 
mutational analysis showed aberrations of the KIT gene. 
While some authors conclude that there is lack of efficacy 
to treat these patients with KIT inhibitors [25, 26], others 
hypothesize that patients with a non-mutated, but amplifi-
cated KIT gene might also benefit of targeted therapies 
[27]. In our five patients (20 %) treated with ipilimumab or 
sorafenib, the use of a targeted therapy was carefully evalu-
ated in a multidisciplinary team in each case.
Treatment with interferon alpha may improve survival 
of patients with high-risk melanomas if used as an adju-
vant (postoperative) treatment [28]. It was given together 
with dacarbazine and taurolidine in one single patient 
(4 %) with local tumor persistence after resection and 
development of regional failure and distant metastasis 
shortly thereafter.
The use of a “conventional” chemotherapy for patients 
with high-risk malignant melanomas of the head and neck 
area is discussed controversially [29]. Despite the lim-
ited and heterogenic data for the use of chemotherapy in 
SNMM, it might be of overall survival benefit in a (neo)
adjuvant setting of patients with distant metastatic disease 
[30]. Six (24 %) of our patients received chemotherapy for 
that purpose. The size of our patient collective, however, 
is far too small to evaluate the results of all the systemic 
therapies.
Other factors
Our limited data did not attribute a prognostic role to the 
tumor localization. Other authors also did not find a rela-
tionship between localization and outcome [2]; there are 
further studies presenting worse results in SNMM originat-
ing from the maxillary sinus, the ethmoid or the sphenoid 
sinus and a better prognosis in septal and/or anterior infe-
rior nasal cavity involvement [5, 15, 31]. These findings 
could be explained by an earlier diagnosis of SNMM in the 
anterior part of the nasal cavity, including the anterior nasal 
septum. Furthermore, there are localizations (for example 
the frontal skull base), in which it is more difficult to obtain 
adequate surgical margins. Consequently, we suspect the 
loco-regional tumor control to be different depending on 
tumor localization.
Limitations of the study
Our study has several limitations. First of all, this is a 
retrospective study on a relatively small number of 
Fig. 1  Disease-free survival (DFS), Disease-specific survival (DSS) 
and overall survival (OS) of patients with sinonasal malignant mela-
noma
Fig. 2  DFS of patients with unilocular (uSNMM) and multilocular 
sinonasal melanoma (mSNMM)
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patients. Consequently, results of the statistical analysis 
have to be carefully interpreted in the light of the small 
cohort. Secondly, the presence of mSNMM is arbitrar-
ily defined on a clinical basis. Despite a careful defini-
tion of multilocularity, a multilocular primary cannot 
be differentiated completely from satellite metastasis or 
skip lesions, which are—of course—related to a worse 
outcome. Nevertheless, we think that the presence of a 
potential multilocular subtype of SNMM and the lack 
of adjuvant therapy with proven efficacy to treat micro-
scopic residual disease should influence the planning of 
future treatment concepts of SNMM and further clinical 
studies.
Conclusions
In almost 30 % of the cases, SNMM show a multilocular 
distribution pattern. mSNMM is associated with an unfa-
vorable DFS compared to its unilocular counterpart.
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